SeromYx Systems utilizes high-throughput assays and machine learning algorithms to analyze humoral immunity, enabling biopharma companies to identify antibody features that predict therapeutic efficacy and vaccine-induced immunity. Their technology provides critical insights into immune function, facilitating the development of effective vaccines, immunotherapies, and diagnostics.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biopharmaceutical companies face challenges in fully characterizing humoral immunity and identifying predictive antibody features for therapeutic efficacy and vaccine-induced protection. Traditional methods often lack the throughput and comprehensive analysis needed to deeply understand antibody function and its correlation to clinical outcomes.
Solution
SeromYx Systems offers a systems serology platform that combines high-throughput assays with advanced computational biology to analyze humoral immunity. The platform enables biopharma to identify antibody features that predict therapeutic efficacy and vaccine-induced immunity. By characterizing both functional and biophysical attributes of antibodies, SeromYx provides insights into the mechanisms of protection. Their approach helps in developing potent antibody therapeutics and effective vaccines by correlating antibody effector function to product efficacy. The platform's machine learning algorithms interpret high-dimensional datasets, avoiding overfitting and providing robust results.
Target Audience
The primary customers are biopharmaceutical companies involved in developing therapeutic antibodies and vaccines.
Features
- High-throughput processing of thousands of samples for robust and repeatable results.
- Comprehensive assay breadth, characterizing both antibody function and biophysical attributes.
- Advanced computational biology with machine learning algorithms to interpret high-dimensional datasets.
- Identification of antibody features that predict successful treatment outcomes for therapeutic antibodies.
- Identification of antibody effector functions correlated with vaccine-induced immunity.
- Customization of projects to client needs with extensive experience of senior staff to interpret results.